Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Oncolytics Biotech (ONCY)
NASDAQ:ONCY
Holding ONCY?
Track your performance easily
Earnings Data
Report Date
Mar 06, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.08Last Year’s EPS
-0.03Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2018
|% Change Since: -26.85%
|Next Earnings Date:Aug 03, 2018
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials for breast and pancreatic cancer, with promising data and potential partnerships enhancing future prospects. Financial management showed a reduction in administrative costs, although R&D expenses increased due to ongoing trials. The company's market opportunity appears substantial, but regulatory and enrollment challenges remain.Company Guidance
During the third quarter of 2024, Oncolytics Biotech reported significant progress in the development of their leading immunotherapeutic agent, pelareorep, particularly in the BRACELET-1 breast cancer study. The combination of pelareorep and paclitaxel demonstrated substantial improvements over paclitaxel monotherapy in key metrics, such as nearly doubling progression-free survival (PFS) to 12.1 months and showing an approximate 14-month benefit in overall survival (OS), with a median OS of 32.1 months. Notably, the 24-month overall survival rate nearly doubled from 33% in the control arm to 64% in the pelareorep arm. These promising results suggest a potential registration-enabling study for HR+/HER2- metastatic breast cancer, aiming for accelerated approval. Additionally, Oncolytics is advancing its gastrointestinal cancer programs, particularly in pancreatic cancer, with ongoing enrollment in GOBLET cohort 5 and collaboration with the Global Coalition for Adaptive Research (GCAR) to finalize a master protocol for an adaptive trial, supported by a $5 million grant from the Pancreatic Cancer Action Network (PanCAN). Financially, the company ended the quarter with $19.6 million in cash, reflecting efficient management of resources, and reported a net loss of $9.5 million, slightly lower than the previous year.BRACELET-1 Study Success
The combination of pelareorep plus paclitaxel showed substantial improvement compared to paclitaxel monotherapy in progression-free survival (PFS) and overall survival (OS). PFS nearly doubled from 6.4 months to 12.1 months, and OS extended from 18.2 months to over 32.1 months in the pelareorep arm.
GOBLET Study in Pancreatic Cancer
Pelareorep-based combination therapy met predefined efficacy success criteria in pancreatic ductal adenocarcinoma, with objective response rates more than double historical rates. Collaboration with GCAR and a $5 million PanCAN grant supports further development.
Financial Management and Resources
As of September 30, 2024, Oncolytics Biotech reported $19.6 million in cash and cash equivalents. General and administrative expenses decreased from $5.2 million to $3.1 million year-over-year for Q3.
Large Market Opportunity
Potential for pelareorep to achieve accelerated approval in HR+/HER2- metastatic breast cancer by 2027, with a projected addressable market of 55,000 patients in the U.S. and potential annual sales of $2.4 billion in the U.S. and EU5 by 2033.
---
ONCY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ONCY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $1.08 | $1.12 | +3.70% |
| Aug 01, 2024 | $1.03 | $1.02 | -0.97% |
| May 09, 2024 | $1.24 | $1.17 | -5.65% |
| Mar 07, 2024 | $1.04 | $1.05 | +0.96% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Oncolytics Biotech (ONCY) report earnings?
Oncolytics Biotech (ONCY) is schdueled to report earning on Mar 06, 2025, TBA Not Confirmed.
What is Oncolytics Biotech (ONCY) earnings time?
Oncolytics Biotech (ONCY) earnings time is at Mar 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ONCY EPS forecast?
ONCY EPS forecast for the fiscal quarter 2024 (Q4) is -0.08.
---